

HORTENSIA - Cohort study in chronic kidney disease patients on dialysis starting treatment with Mircera® to correct anemia or maintain stable hemoglobin levels

Head :Roche Medical Data Center

Last update : 08/23/2022 | Version : 1 | ID : 74133

General

Identification

Detailed name	Cohort study in chronic kidney disease patients on dialysis starting treatment with Mircera® to correct anemia or maintain stable hemoglobin levels
Sign or acronym	HORTENSIA

General Aspects

Medical area	Urology, andrology and nephrology
Study in connection with Covid-19	No
Pathology (details)	Chronic Kidney Disease on dialysis
Health determinants	Iatrogenic Medicine
Keywords	MIRCERA®

Scientific investigator(s) (Contact)

Name of the director	Roche Medical Data Center
Address	4 cours de l'Île Seguin - 92650 BOULOGNE-BILLANCOURT
Email	data_sharing_france@roche.com
Organization	Roche SAS

Collaborations

Participation in projects, networks and consortia	No
---	----

Funding

Funding status	Private
----------------	---------

Governance of the database

Sponsor(s) or organisation(s) responsible Roche SAS

Organisation status Public

Presence of scientific or steering committees Yes

Additional contact

Name of the contact <https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html>

Main features

Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is made on the basis of: Medication(s) taken

Database recruitment is carried out as part of an interventional study No

Database objective

Main objective

Primary objective: Describe the management of anemia treatment with Mircera® in routine clinical practice in chronic kidney disease patients on dialysis and to describe their hemoglobin concentration around the 6th month of treatment with Mircera®.

Secondary objective:
In the total population and in each sub-population of patients (hemodialysis and peritoneal dialysis, ESA-naive and non ESA-naive patients):

1. Describe the characteristics of patients treated with Mircera®;
2. Describe the evolution of Hb and hematocrit levels during the observation period;
3. Describe the biological parameters used to

- document renal anemia and any changes in values;
4. Describe the parameters influencing treatment response;
 5. Describe the biological parameters reflecting the efficacy of dialysis;
 6. Describe the safety profile of Mircera® (serious and/or unexpected adverse drug reactions and targeted adverse drug reactions related to Mircera®);
 7. Describe treatment compliance with Mircera®;
 8. Describe the evolution of patients' quality of life, evaluated by the SF-36 questionnaire.

Inclusion criteria

Inclusion criteria:

- Adult (aged \geq 18 years);
- With CKD and on dialysis for more than 3 months;
- ESA-naive or not;
- For whom the physician decided to initiate treatment with Mircera® for renal anemia at the inclusion visit;
- Who was informed about the study both orally and in writing and who did not object to their personal data being processed.

Exclusion criteria:

- Patient participating in a clinical study;
- Anemia due to a malignant disease.

Population type

Age

Adulthood (19 to 24 years)
 Adulthood (25 to 44 years)
 Adulthood (45 to 64 years)
 Elderly (65 to 79 years)
 Great age (80 years and more)

Population covered

Sick population

Pathology

N18 - Chronic kidney disease

Gender

Male
 Woman

Geography area

National

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)

2010

Date of last collection (YYYY or

2011

MM/YYYY)

Size of the database

Size of the database (number of individuals) < 500 individuals

Details of the number of individuals 414

Data

Database activity Data collection completed

Type of data collected Clinical data
Biological data

Clinical data (detail) Medical registration

Details of collected clinical data Patient provided with information about the study - Demographic and clinical data, concomitant diseases - History of chronic renal failure and dialysis - Previous treatment for CKD-associated anemia: with ESA if any and other potential treatments (iron, folic acid, vitamin B12, blood transfusion over the last 3 months before Mircera® initiation) - Clinical data at the midweek dialysis session: weight after the session, blood pressure at rest and after the session - Most recent available laboratory data: urea and serum creatinine (before and after the dialysis session), urea reduction ratio, Kt/V (hemodialysis), total Kt/V (peritoneal dialysis), Hb, hematocrit, platelet count, reticulocytes, iron status, C-reactive protein, documented deficiency in folic acid or vitamin B12 if any - Treatment of CKD-associated anemia at inclusion: treatment with Mircera® and concomitant treatment if any (iron, folic acid, vitamin B12) - Other treatments: antihypertensives, antiplatelet drugs, anticoagulants, LMWH, lipid-lowering treatments, antidiabetics, immunosuppressors.

Presence of a biobank No

Health parameters studied Health care consumption and services

Care consumption (detail) Medicines consumption

Procedures

Data collection method paper

Classifications used CDISC

Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Links to administrative sources	No

Promotion and access

Promotion

Access

Dedicated website	https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html
Presence of document that lists variables and coding procedures	Yes
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only